Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP: PHRRF )

0.0972 +0.0017 (+1.78%)
Streaming Delayed Price Updated: 12:01 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 70,490
Open 0.1004
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0955
Today's Range 0.0943 - 0.1025
52wk Range 0.0368 - 0.2180
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind
Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through... 
Via Benzinga

Performance

YTD
+94.40%
+94.40%
1 Month
-26.25%
-26.25%
3 Month
+88.74%
+88.74%
6 Month
-2.80%
-2.80%
1 Year
-48.57%
-48.57%

More News

Read More
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Via Benzinga
PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Via Benzinga
PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
From PharmaTher Holdings Ltd.
Via Globe NewsWire
Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
Via Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Via Benzinga
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via Globe NewsWire
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Via Benzinga
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
From PharmaTher Holdings Ltd.
Via Globe NewsWire
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via Globe NewsWire
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Via Benzinga
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Via Benzinga
Psychedelics Market Could Reach $12B By 2029, Says New Report
Via Benzinga
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
From PharmaTher Holdings Ltd.
Via Globe NewsWire
2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products
Via Benzinga
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
From PharmaTher Holdings Ltd.
Via Globe NewsWire
FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status
Via Benzinga
PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
From PharmaTher Holdings Ltd.
Via Globe NewsWire
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
From PharmaTher Holdings Ltd.
Via Globe NewsWire
Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder
Via Benzinga
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
From PharmaTher Holdings Ltd.
Via Globe NewsWire
Ketamine for Parkinson's Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It
Via Benzinga
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via Globe NewsWire
PharmaTher Provides Business Highlights And Releases Audited Annual Financials
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.